Reference solutions for drug interference testing, 11/15
November 2015—Sigma-Aldrich’s Cerilliant brand now offers reference solutions for qualitative evaluation of drug interferences in a testing laboratory’s analytical methods.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Siemens joins CANCER-ID consortium , 11/15
November 2015—Siemens Healthcare has joined the CANCER-ID consortium, an initiative of the European Union’s Innovative Medicines Initiative, to explore the potential of blood-based biomarkers in the detection and treatment of cancer.
Method evaluation standards, 11/15
November 2015—CLSI released new and revised standards on method evaluation titled “A Framework for Using CLSI Documents to Evaluate Clinical Laboratory Measurement Procedures (EP19-Ed2).”
Chip prep module, 11/15
November 2015—Agena Bioscience introduced the Chip prep moduleto automate sample handling after polymerase chain reaction for the MassArray 96-well System. This enables laboratories to operate the MassArray System largely unattended for high-throughput, multiplex genetic analysis.
Micropolymer IHC systems, 11/15
November 2015—Bio SB PolyDetector Systems are highly sensitive micropolymeric detection systems that allow for the demonstration of antigens in formalin-fixed, paraffin-embedded tissues, cryostat sections, blood smears, cytosmears, and cell preparations.
Whole exome sequencing solution, 11/15
November 2015—Roche has launched the SeqCap EZ Med-Exome Target Enrichment Kit, a comprehensive whole exome sequencing solution designed to increase the discovery and detection of human genetic variants associated with disease while reducing sequencing costs. For research use only; not for use in diagnostic procedures.
Carbonic anhydrase IX automated IHC kit, 11/15
November 2015—Nuclea Biotechnologies has met the requirements from the FDA for its Carbonic Anhydrase IX Automated immunohistochemistry kit as a class I in vitro diagnostic device for use on a Ventana Benchmark XT instrument.
CE mark for human serum albumin, 11/15
November 2015—Irvine Scientific received CE mark approval for its Human Serum Albumin Solution (100 mg/mL) in normal saline. HSA is used in assisted reproductive procedures as a protein supplement for gamete and embryo manipulation.
NGS cancer panel, 11/15
November 2015—Illumina has launched TruSight Tumor 15, a next-generation sequencing panel designed to identify sequence variants in 15 genes commonly associated with marketed therapeutics. The sequencing panel is optimized for damaged and degraded formalin-fixed, paraffin-embedded tumor samples, enabling low frequency somatic variant detection from limited nucleic acid inputs.
Calibration verification/linearity test kit, 11/15
November 2015—Maine Standards released its Validate SP2 calibration verification/linearity test kit, which evaluates albumin, C-reactive protein, haptoglobin, and prealbumin in a human-serum–based matrix.